Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx reported Q3 2026 revenue of $22.8 million, up 6% year over year, with U.S. revenue up 7% and international revenue up 5%. Adjusted EBITDA loss narrowed 57% to $3.5 million, gross margin increased to 76% from 75%, and GAAP net loss fell to $8.4 million from $14.0 million. Management reiterated 2026 revenue guidance of $90 million–$92 million and raised expected gross margin to approximately 77%; it also expects to resume China distributor shipments by early 2027, while noting that China revenue is relatively small and lumpy.

Analysis

The key change is operating leverage beginning to work alongside revenue growth—not yet proof of a durable acceleration. The strongest near-term test is whether U.S. same-center activity converts into procedures as a salesforce with short tenure matures. That creates upside over the next 1–3 quarters, but also execution risk: staffing coverage is not the same as rep productivity, and management could not isolate which initiatives drove the quarter. Track U.S. growth and treating-center utilization rather than new-center adds alone.

China is a secondary catalyst, not a thesis. Even a successful shipment restart is small relative to the business and distributor timing is lumpy; the return of distributor mix may also dilute gross margin gains. The more consequential margin question is whether supply-chain efficiencies persist as volume and mix change. Cash burn is improving, but the additional facility capital is conditional on revenue milestones, so it should not be treated as unconditional runway.

AeriSeal is long-dated optionality, not a 2027 earnings driver: trial enrollment completion is targeted for 2H27 and a limited European launch precedes more material contribution. The contrarian read is that investors may over-credit one quarter of growth and cost cuts as a new growth trajectory, while underweighting the upside if newer reps reactivate existing accounts and deliver high-margin incremental sales. Without valuation, price action, or consensus data, conviction on risk/reward is insufficient for an outright directional position.

Key Decisions for Investors

• No immediate fundamental trade absent valuation and post-results price data. Reassess after the next quarter: sustained U.S. growth with evidence of same-center procedure gains would support a small tactical long in LUNG; renewed U.S. contraction would invalidate the recovery thesis.
• Treat China as a monitoring item, not a reason to pay for near-term growth. Verify actual shipment timing and revenue, and watch consolidated gross margin for deterioration as distributor sales resume.
• Model AeriSeal as a 2028+ catalyst rather than near-term revenue. Alert on CONVERT II enrollment pace, trial milestones, and any change to the planned European launch sequence.
• Stress-test liquidity using cash burn and the credit facility separately; confirm the revenue milestones required to access the additional capital. A missed milestone or cash burn materially above guidance would weaken the operating-leverage case.